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Purpose: To evaluate the response to aﬂibercept therapy for Type 1 and Type 3
neovascularization in pigment epithelial detachments associated with treatment-naive,
neovascular age-related macular degeneration.
Methods: In this multicentered, prospective study, eligible eyes underwent an intravitreal
aﬂibercept injection protocol for 12 months. Visual acuity and morphologic features of the
pigment epithelial detachments were compared at baseline and follow-up intervals
between eyes with Type 1 versus Type 3 neovascularization.
Results: Thirty-six eyes were analyzed. At 12 months, Type 1 lesions showed a 4.5 ± 23
Early Treatment of Diabetic Retinopathy Study letter improvement (P = 0.1665) versus
a 14 ± 11 (P = 0.0072) letter improvement with Type 3 lesions. Both Type 1 and 3 eyes
showed a signiﬁcant decrease in pigment epithelial detachment size, subretinal ﬂuid, and
subretinal hyperreﬂective material; however, Type 3 eyes had a greater reduction in pig-
ment epithelial detachment size and subretinal hyperreﬂective material, as well as a reduc-
tion in central retinal thickness. Type 1 eyes required an average of 1.636 (range, 1–4)
injections to resolve ﬂuid, which was greater than Type 3 eyes, which required an average
of 1.143 (range, 1–2) injections (P = 0.0251).
Conclusion: Intravitreal aﬂibercept injections were efﬁcacious for pigment epithelial
detachments, but baseline and follow-up anatomical and functional outcomes differed in
Type 1 versus Type 3 neovascularization. The better response of Type 3 eyes with fewer
injections suggests that differentiation of the neovascularization subtype at the initial
diagnosis may allow for a more tailored, optimal therapy.
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Serous and ﬁbrovascular pigment epithelial detach-ments (PEDs) have been estimated to be present in
63% of eyes with neovascular age-related macular degen-
eration (AMD)1 and are predominantly the result of either
Type 1 or Type 3 neovascularization (NV). Type 1 NV
originates from the choroid and is located underneath the
retinal pigment epithelium (RPE), whereas Type 3 NV,
also known as retinal angiomatous proliferation, gener-
ally originates from the deep retinal capillary plexus
(DCP) within the retina.2 Type 1 and Type 3 membranes
comprise nearly 90% of lesions in neovascular AMD.3
Pigment epithelial detachments in neovascular AMD
can be challenging to treat and may be more resistant to
anti-vascular endothelial growth factor (anti-VEGF)
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therapy with worse visual outcomes.4,5 Although all sub-
groups of neovascular AMD have shown visual and
anatomical beneﬁts with any of the 3 major intravitreal
anti-VEGF agents (bevacizumab, ranibizumab, and aﬂi-
bercept), certain studies have indicated that the visual
outcomes may not be as favorable in eyes with PEDs.4,5
None of these studies, however, have differentiated treat-
ment response based on the subtype of NV. In fact, to
date, there has been no prospective study comparing the
effects of intravitreal aﬂibercept injections on treatment-
naive PEDs due to Type 1 versus Type 3 NV in AMD.
The aim of this subanalysis study was to compare the
clinical and multimodal imaging features of eyes with
PEDs due to Type 1 versus Type 3 NV at baseline and
to assess their comparative visual and anatomical
response to intravitreal aﬂibercept injections in a pro-
spective investigation. Visual and anatomical outcomes
of the PED cohort as a whole will be published in
a separate study.
Methods
Study Design
This multicentered trial was a prospective, noncon-
trolled, open-labeled, interventional, comparative clin-
ical investigation. Institutional review board approval
was obtained before the beginning of the study. The
research trial adhered to the tenets of the Declaration of
Helsinki and was conducted in accord with regulations
set forth by the Health Insurance Portability and
Accountability Act. All participants signed a written
informed consent.
Patients at least 50 years of age with treatment-
naive, active, neovascular AMD, submacular PED
less than 12 disk areas with foveal involvement, and
evidence of intraretinal ﬂuid (IRF) and/or subretinal
ﬂuid (SRF) were enrolled for prospective assessment
of visual outcomes from baseline to 12 months and
prospective evaluation of lesion ﬁndings using mul-
timodal imaging analysis. Vision criteria for recruit-
ment included Early Treatment of Diabetic
Retinopathy Study (ETDRS) best-corrected visual
acuity (BCVA) between 19 and 73 letters (Snellen
20/35–20/400) in the affected eye. Pigment epithelial
detachments were deﬁned by multimodal retinal
imaging with the following characteristics. A well-
circumscribed, orange or yellow, oval or bean-
shaped elevation of the RPE with a smooth, convex
surface with or without a notch. Fluorescein angiog-
raphy (FA) criteria included areas of uniform or leak-
age with or without a hot spot. Spectral domain
optical coherence tomography (SD-OCT) criteria
included a discrete, well-deﬁned elevation of the
RPE with a hyporeﬂective serous or a mixed reﬂec-
tive ﬁbrovascular compartment. Pigment epithelial
detachments had to demonstrate a focus of NV with
angiography and SD-OCT. Clinical ophthalmoscopic
examination and color fundus photography show
a polyploidal choroidal vasculopathy lesions were
excluded. Table 1 provides the full list of inclusion
and exclusion criteria.
If both eyes of a patient were found to be eligible,
then only one eye was selected to be included in the
study. Patients did not undergo any form of intraocular
surgery during the time of study.
Outcome Measures
The primary outcome was ETDRS BCVA at ﬁnal
follow-up of 12 months. Secondary outcome measures
included the prevalence and volumetric measurements
of speciﬁc morphologic features as seen on SD-OCT.
These features included PED size (maximal height and
volume), IRF, SRF, subretinal hyperreﬂective material
(SRHRM), retinal thickness, geographic atrophy, and
multilayering of ﬁbrovascular material within PEDs.
Ocular and systemic adverse events were also recorded.
Treatment Schedule
All study eyes received 6 monthly intravitreal
injections of 2.0 mg/0.05 mL of aﬂibercept followed
by 3 bimonthly injections. An additional 3 injections
From the *Department of Ophthalmology, David Geffen School of
Medicine, Stein Eye Institute, University of California Los Angeles, Los
Angeles, California; †Department of Ophthalmology, David Geffen
School of Medicine, Doheny Eye Institute, University of California
Los Angeles, Los Angeles, California; ‡Southern California Desert
Retina Consultants, Palm Desert, California; §Department of Ophthal-
mology, Loma Linda University Eye Institute, Loma Linda, California;
¶Black Hills Regional Eye Institute, Rapid City, South Dakota; and
**Department of Ophthalmology, Greater Los Angeles Veterans Affairs
Healthcare System, Los Angeles, CA.
Supported by a research grant from Regeneron. No support was
received from the NIH, Wellcome Trust, or HHMI. C. K. Chan
receives research support from Genentech, NEI, Acucela, Ophthotech,
Sequenom, Regeneron, Allergan, and Theratechnologies. P. Abraham
receives research support from Allergan, Genentech, NEI, Juvenile
Diabetes Research Foundation, Ophthotech, Pﬁzer, Schering-
Plough, and Thrombogenics. M. Lalezary and S. G. Lin receive
research support from Allergan, Acucela, Regeneron, Genentech,
Ophthotect, and NEI. D. Sarraf has research grants from Regeneron,
Genentech, and Optovue. S. Sadda is a consultant for Optos, Carl
Zeiss Meditec, Allergan, Genentech, Regeneron, Bayer, Novartis, and
Iconic and receives research support from Optos, Carl Zeiss Meditec,
Allergan, and Genentech. X. Chen, M. Al-Sheikh, and A. H. Hariri
have no ﬁnancial disclosures.
The preliminary results of this article were presented at the
International Retinal Imaging Symposium IV, March 19, 2016,
Los Angeles, CA.
None of the authors have any conﬂicting interests to disclose.
Reprint requests: David Sarraf, MD, Retinal Disorders and
Ophthalmic Genetics Division, Stein Eye Institute, University of
California Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095;
e-mail: dsarraf@ucla.edu
2 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2016  VOLUME 0  NUMBER 0
Copyright ª by Ophthalmic Communications Society, Inc. Unauthorized reproduction of this article is prohibited.
were allowed 1 month after the most recent injection
on a pro re nata basis during the second 6-month
period. Pro re nata features warranting injection
included recurrence of IRF and/or SRF.
Assessment Schedule
A complete ocular examination, including ETDRS
BCVA, biomicroscopic examination of the anterior
segment and posterior pole of the retina, and indirect
ophthalmoscopy of the retinal periphery, was performed
for all patients. Spectral domain optical coherence
tomography (Spectralis, Heidelberg Engineering,
Heidelberg, Germany) using high-density scans was
performed at baseline and then monthly for 12 months.
Fluorescein angiography (Carl Zeiss Meditec, Dublin,
CA) and color fundus photography (Carl Zeiss Meditec)
were performed at baseline, 3 months, 6 months, and 12
months. Indocyanine green angiography (ICG; Carl Zeiss
Meditec, Dublin, CA) was performed at baseline and 12
months.
Multimodal Imaging Assessments
All multimodal images including FA, ICG, and SD-
OCT were sent to a third-party reading center (Doheny
Image Reading Center [DIRC], Los Angeles, CA) for
qualitative and quantitative measurements of NV, PEDs,
and geographic atrophy. The grading protocol necessi-
tated the grader to meticulously draw multiple bound-
aries on all OCT B-scans to manually segment the
various structures of interest. The previously described
and validated DIRC OCT grading software, OCTOR,6,7
then applied a linear interpolation algorithm between the
B-scans to generate volume and thickness maps. The
foveal centers of all images were marked and ETDRS
subﬁelds were generated based on that foveal center for
each SD-OCT. Additional qualitative review of the im-
ages was performed as part of the data analysis.
Image Analysis
After all data were collected, the PEDs were catego-
rized into 3 groups: Type 1, Type 3, or mixed/other NV
subtype based on analysis of their baseline SD-OCT,
color fundus photography, FA, and ICG. Each case was
classiﬁed according to the guidelines provided by
Freund et al.8 Type 1 NV was deﬁned on SD-OCT as
sub-RPE neovascular lesions associated with a PED
comprised of vascular (heterogenous or multilayered re-
ﬂectivity), serous (hyporeﬂective), or mixed components
and on dye-based angiography as a hotspot associated
with the PED or stippled late leakage with FA. Type 3
NVwas identiﬁed on SD-OCT by the presence of a char-
acteristic, intraretinal hyperreﬂective focus within the
outer nuclear layer with or without associated IRF
as described in previous articles2,9–11 and conﬁrmed
by correlation with fundus photography showing
a pinpoint intraretinal hemorrhage and FA and ICG
showing a hotspot of angiographic leakage. Any eyes
with more than 1 subtype of NV or Type 2 NV (clas-
sic, well-deﬁned NV on FA or hyperreﬂective NV
present within the subneurosensory compartment on
SD-OCT) were excluded from analysis.
The presence of reticular pseudodrusen was evalu-
ated by near infrared reﬂectance and SD-OCT. The
presence of ﬁbrovascular layering12 and lipid bands
within the PEDs, RPE tears, and geographic atrophy
were also recorded.
Statistical Analysis
Statistical analysis was performed using Microsoft
Excel 2011 version 14 (Microsoft Corporation,
Table 1. Inclusion and Exclusion Criteria for the Study
Inclusion criteria
1. $50 years of age
2. Study eye contains a submacular ﬁbrovascular PED
#12 disk area
3. Central foveal involvement by the PED or NV related
to AMD (NV maybe within or adjacent to the margin of
PED)
4. ETDRS BCVA $19 letters and #73 letters (20/400–
20/35)
5. Evidence of submacular ﬂuid outside or surrounding
the PED
Exclusion criteria
1. Any previous treatment for exudative AMD in the
study eye
2. Previous periorbital therapeutic radiation
3. Previous RPE tear in the study eye
4. Previous ocular surgery (except laser capsulotomy)
within past 90 days or anticipated surgery (except
laser capsulotomy) within the next 12 months
5. Previous vitrectomy
6. Presence of any causes for NV and PED other than
AMD
7. Presence of any substantial ocular disease (other than
NV and PED) that may compromise vision and
confound interpretation of data
8. Serous PED without NV and PCV lesions
9. Surface area of any submacular hemorrhage or
ﬁbrosis .50% of the PED
10. Active ocular infection during screening
11. IOP #25 mmHg with or without use of ocular
hypotensive agents
12. Previous or current systemic anti-VEGF
13. Previous (within 90 days) or current oral or intravenous
corticosteroid treatment
14. Sexually active men or women of child-bearing
potential who are unwilling to practice contraception
IOP, intraocular pressure; PCV, polyploidal choroidal vascul-
opathy.
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Redmond, WA) with SAS Add-In 6.1 for Microsoft
Ofﬁce and GraphPad QuickCalcs (http://www.
graphpad.com/quickcalcs/). Differences between Type
1 and Type 3 NV were calculated using independent
t-tests assuming unequal variances for scaled variables
and Fisher exact tests for categorical variables. The
paired t-test was used to compare scaled variables at
baseline and ﬁnal 12-month follow-up within each
lesion group. Simple linear regression modeling was
performed between SD-OCT morphologic features
and baseline and ﬁnal visual acuity. Two-tailed statis-
tics was used for all calculations. Linear discriminant
analysis was performed to evaluate the inﬂuence of
baseline parameters on the development of geographic
atrophy. Missing variables were not imputed. Statisti-
cal signiﬁcance was set at 0.05.
Results
A total of 40 eyes from 40 patients were enrolled in
the study from 3 centers. Four eyes were excluded
from all analysis in this article because one demon-
strated a vitelliform-like lesion not characteristic of
AMD, one showed Type 2 lesion components, one had
signiﬁcant retinal distortion from an epiretinal mem-
brane confounding analysis, and one showed Type 1
and Type 3 lesion components. Of the remaining 36
patients, 28 (78%) patients were found to have Type 1
Fig. 1. Multimodal imaging of a PED due to Type 1 NV at baseline and at follow-up. A. Color fundus photography at baseline showed a PED in the
absence of hemorrhage. B. Near-infrared image of the PED at baseline showed patches of hyperreﬂectivity over the PED. (C) Late FA at baseline
demonstrated progressive pooling and leakage within the PED and blockage from speckled pigmentation. (D) Late FA at month 3 showed reduced
PED pooling and leakage indicating regression of NV. (E) Indocyanine green angiography (ICG) at baseline demonstrated a neovascular complex at
the nasal edge of the PED (arrow). (F) ICG at Month 3 showed increased staining within the PED with persistence of the nasal neovascular complex
(arrow). (G) SD-OCT B-scans through the white line in (B) that cut through the nasal neovascular complex showed that the treatment-naive PED
was largely serous with a Type 1 neovascular component at the nasal edge of the PED with associated RPE corrugations (dotted arrow) due to
traction. With 1 injection, the PED collapsed (Week 4 and Month 6) and the SRF resolved. Note the onset of geographic atrophy over time as seen
in Month 12 (arrow head).
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lesions and 8 (22%) patients were found to have Type
3 lesions. Figure 1 and Figure 2 illustrate typical Type
1 and Type 3 lesions. The Type 1 group had 11 males
and 17 females, and the Type 3 group had 2 males and
6 females (P = 0.6820). The Type 1 group had a mean
age of 78 years (range 65–90), whereas the Type 3
group had a mean age of 84 years (range 67–98) (P =
0.1110). Table 2 illustrates the baseline characteristics
by neovascular subtype.
Three patients (2 Type 1 lesions and 1 Type 3
lesion) did not complete the study and were excluded
for all analysis requiring longitudinal data beyond
their last visit. Five Type 1 eyes developed RPE tears
(3 grade 3 tears after 1, 4, and 5 injections and 2 grade
4 tears both after 1 injection), whereas none of the
Type 3 eyes developed RPE tears. These 5 eyes with
RPE tears were analyzed as a separate group from the
remaining Type 1 lesions.
Table 2. Baseline Demographics and Vision of All Included Eyes Separated by NV Type
All Patients (n = 36) Type 1 (n = 28) Type 3 (n = 8) P
Age, years 80 ± 8.0 78 ± 6.8 84 ± 11 0.1110
Sex 23 F 17 F 6 F 0.6820
13 M 11 M 2 M
BCVA (ETDRS) 59 ± 8.9 (Snellen 20/66) 60 ± 8.7 (Snellen 20/63) 56 ± 9.7 (Snellen 20/76) 0.1780
There was no statistical difference in baseline demographics or vision for Type 1 and Type 3 patients. There was an overall greater
presence of females in both groups, consistent with the AMD populations.
Fig. 2. Multimodal imaging of a PED due to Type 3 NV at baseline and at follow-up. At baseline, (A) color fundus photography showed exudates and
a pinpoint hemorrhage (arrow) adjacent to an arteriole, and the (B) near-infrared image showed speckled hyperreﬂectance over the dark PED. C. The early FA
demonstrated a hotspot (arrow) corresponding to the intraretinal neovascular complex and associated with the spot hemorrhage seen in (A), and (D) late FA
frames showed diffuse pooling and leakage around the PED. G. Baseline indocyanine green angiography (ICG) also showed the hotspot (arrow). I. Baseline
SD-OCT showed a hyperreﬂective focus corresponding to the intraretinal NV with associated IRF. With 1 injection, the PED collapsed and the IRF resolved
which is clearly seen on with SD-OCT (Week 4); and with progressive injections, a small subretinal scar developed corresponding to the Type 3 lesion (I,
arrow head, Week 4 and Month 12). Note the resolution of leakage on (E) early and (F) late FA and (H) ICG at the Month-3 interval.
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Visual Acuity Analysis
The baseline ETDRS BCVA ± SD was 59 ± 8.9
letters (Snellen 20/66) for all lesions, 60 ± 8.7 letters
(Snellen 20/63) for Type 1 lesions, and 56 ± 9.7
letters (Snellen 20/76) for Type 3 lesions (P =
0.1780).13 The BCVA at ﬁnal 12-month follow-up
was 65 ± 27 letters (Snellen 20/50) for all lesions,
64 ± 27 letters (Snellen 20/53) for Type 1 lesions, and
70 ± 28 letters (Snellen 20/40) for Type 3 lesions (P =
0.1971 between Type 1 and Type 3 lesions, including
eyes with RPE tears but excluding those who did not
ﬁnish the study).
At ﬁnal 12-month follow-up, all eyes showed
a 6.5 ± 22 letters improvement. Type 1 eyes showed
an overall improvement of 4.5 ± 23 letters (P =
0.1665) and an improvement of 7.5 ± 19 letters in
Fig. 3. Functional and anatom-
ical outcomes over time for Type
1 lesions that did not develop
RPE tears, Type 1 lesions that
developed RPE tears, and Type
3 lesions. A. Both Type 1 eyes
without RPE tears and Type 3
eyes showed vision improve-
ment from baseline to ﬁnal 12-
month follow-up; however,
Type 3 eyes showed a 9.2
greater letter gain in vision. By
contrast, Type 1 eyes with RPE
tears showed a vision decrease
with a greater SD. (B and C)
Maximal PED height and PED
volume both showed decreases
in all 3 groups over time. Type 1
eyes without RPE tears and
Type 3 eyes had similar baseline
PED sizes; however, given the
greatest decrease over time for
Type 3 eyes, the Type 3 group
demonstrated a smaller 12
months PED size. Type 1 eyes
with RPE tears, however,
showed a greater PED size at all
time points. D. Type 3 eyes had
a higher CRT than Type 1 eyes
at baseline but showed a signiﬁ-
cant decrease within 8 weeks.
Type 1 eyes with RPE tears had
a consistently greater average
CRT compared with Type 1 eyes
that never experienced an RPE
tear; however, the difference at
baseline and ﬁnal 12-month fol-
low-up was not signiﬁcant likely
because of the small sample size
and the high variation within the
group without RPE tears. E.
Type 1 eyes with RPE tears had
the greatest initial total SRF
volume and Type 3 eyes had the
least SRF volume. All 3 groups
showed a decrease in SRF vol-
ume over time, but and Type 1
eyes without RPE tears and
Type 3 eyes showed a quick
reduction toward 0. F. Baseline
SRHRM was greater for Type 1
eyes with RPE tears, which
showed an initial average
decrease followed by an
increase. The Type 1 eyes with-
out RPE tears and Type 3 eyes
all began with similar total
SRHRM volume and both
showed a rapid decrease with time. Error bars represent SE.
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the group of eyes that did not develop a RPE tears
(P = 0.0454) and a decrease of 7.8 ± 37 letters in the
group of eyes that developed a tear (P = 0.3292).
Type 3 lesions showed an improvement of 14 ± 11
letters (P = 0.0072). Type 3 lesions had an overall
9.2 greater gain in ETDRS letters at the conclusion
of the study as compared with the Type 1 lesion
group with a P value of 0.0734. Figures 3 and 4 show
the visual acuity trends throughout the study.
Spectral Domain Optical Coherence
Tomography Analysis
Baseline SD-OCT characteristics between the lesion
types are outlined in Table 3. Notable differences that
reached statistical signiﬁcance between Type 1 and Type
3 lesions included the greater presence of IRF, DCP
exudates, and reticular pseudodrusen in Type 3 lesions
at baseline. Type 1 lesions showed a trend toward greater
presence of SRF and multilayering at baseline.
Fig. 4. Functional and ana-
tomic outcomes over time for
all Type 1 lesions versus Type 3
lesions. The green line repre-
sents all 28 Type 1, solid le-
sions, and the red, dotted line
represents all 8 Type 3 lesions.
All trends for Type 1 lesions are
similar to the trends in Type 1
lesions without RPE tears
illustrated in Fig. 3. A. Type 1
lesions showed an overall
improvement of 4.5 ± 23 letters,
and Type 3 lesions showed an
improvement of 14 ± 11 letters.
There was no statistically sig-
niﬁcant difference at baseline or
ﬁnal BCVA between the 2
groups (P = 0.1780 for baseline,
P = 0.1971 for ﬁnal 12-month
follow-up). Additionally, Type
1 lesions did not show a statis-
tically signiﬁcant change in
vision (P = 0.1665). (B and C)
All Type 1 lesions showed
a statistically signiﬁcant
decrease in PED size from
baseline to ﬁnal follow-up (P =
0.0001 for PED maximal
height, P = 0.0008 for PED
volume) and a statistically sig-
niﬁcant difference from Type 3
lesions at ﬁnal follow-up (P =
0.0005 for PED maximal
height, P = 0.0008 for PED
volume). D. CRT was statisti-
cally different at baseline
between Type 1 and Type 3
eyes (P = 0.0009) but not dif-
ferent at ﬁnal follow-up (P =
0.3436). Type 1 eyes did not
show a statistically signiﬁcant
change in CRT from baseline to
ﬁnal follow-up, whereas Type 3
eyes showed a signiﬁcant
decrease. E. The 2 lesion
groups showed a signiﬁcant
difference at baseline (P =
0.0059) and follow-up (P =
0.0501) for SRF volume. The
aggregate Type 1 group also
showed a decrease in SRF vol-
ume (P = 0.0008). (F) SRHRM
volume was statistically differ-
ent at ﬁnal follow-up between
Type 1 and Type 3 (P = 0.0108) given the signiﬁcant decrease in Type 1 eyes (P = 0.0036) and Type 3 (P = 0.0419) eyes.
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As illustrated in Table 4, at baseline, central retinal
thickness (CRT) (226 ± 99 mm for Type 1 without
RPE tears, 294 ± 168 mm for Type 1 with RPE
tears, 352 ± 70 mm for Type 3) was signiﬁcantly
greater with Type 3 lesions, and SRF volume
(0.53 ± 0.47 mm3 for Type 1 without RPE tears,
1.8 ± 2.0 mm3 for Type 1 with RPE tears, and
0.18 ± 0.27 mm3 for Type 3) was statistically greater
with Type 1 lesions.
At 12-month follow-up, CRT (213 ± 99 mm for
Type 1 without RPE tears, 308 ± 170 mm for Type 1
with RPE tears, and 239 ± 112 mm for Type 3) re-
mained greater in Type 3 eyes as compared with Type
1 eyes without RPE tears, but SRF volume (0.012 ±
0.024 mm3 for Type 1 without RPE tears, 0.16 ± 0.26
mm3 for Type 1 with RPE tears, and 0 mm3 for Type
3), maximal PED height (166 ± 144 mm for Type 1
without RPE tears, 469 ± 258 mm for Type 1 with RPE
tears, and 43 ± 59 mm for Type 3), PED volume (0.41
± 0.46 mm3 for Type 1 without RPE tears, 1.2 ±
1.1 mm3 for Type 1 with RPE tears, and 0.017 ±
0.024 mm3 for Type 3), and SRHRM volume (0.091
± 0.16 mm3 for Type 1 without RPE tears, 0.30 ±
0.49 mm3 for Type 1 with RPE tears, and 0.0033 ±
0.0071 mm3 for Type 3) were all statistically greater
with Type 1 eyes without RPE tears than Type 3 eyes.
Additionally, at baseline, Type 1 eyes with RPE
tears had a signiﬁcantly greater maximal PED height
(333 ± 199 mm for Type 1 without RPE tears and
849 ± 256 mm for Type 1 with RPE tears), a signiﬁ-
cantly greater PED volume (0.97 ± 0.99 mm3 for Type
1 without RPE tears and 4.2 ± 2.5 mm3 for Type 1
with RPE tears), and a trend toward greater SRHRM
volume (0.42 ± 0.47 mm3 for Type 1 without RPE
tears and 0.90 ± 0.62 mm3 for Type 1 with RPE tears)
than Type 1 lesions that did not sustain tears.
Within each lesion group, both Type 1 and Type 3
lesions showed a statistically signiﬁcant decrease from
baseline in the maximal PED height (P = 0.0010 for
Type 1 without RPE tears, P = 0.0320 for Type 1 with
RPE tears, and P = 0.0060 for Type 3) and PED
volume (P = 0.0054 for Type 1 without RPE tears,
P = 0.0133 for Type 1 with RPE tears, and P = 0.0112
for Type 3). Additionally, the ﬁnal SRHRM volume
showed a decrease from baseline for Type 1 without
RPE tears and Type 3 lesions (P = 0.0088 for Type 1
without RPE tears, P = 0.1223 for Type 1 with RPE
tears, and P = 0.0419 for Type 3). For CRT, Type 3
lesions showed a statistically signiﬁcant decrease from
baseline, whereas Type 1 lesions did not (P = 0.1208
for Type 1 without RPE tears, P = 0.4528 for Type 1
with RPE tears, and P = 0.0073 for Type 3). Type 1
lesions without RPE tears showed a statistically sig-
niﬁcant decrease in SRF volume from baseline,
whereas Type 1 lesions with RPE tears and Type 3
lesions showed a trend in decrease (P ,0.0001 for
Type 1 without RPE tears, P = 0.0778 for Type 1 with
RPE tears, and P = 0.0605 for Type 3). Table 4 sum-
marizes the differences between the groups, and
Figure 3 and Figure 4 illustrate the anatomical trends.
Five of 28 (18%) Type 1 lesions had a hyper-
reﬂective focus above the RPE layer similar to Type 3
lesions except that there was no associated disruption
of the RPE or disorganization of the inner retina. Fig-
ure 5 shows these 5 “pseudo-hyperreﬂective focus”
and the 8 Type 3 lesions in comparison.
Twenty-one of 28 (75%) Type 1 eyes showed RPE
corrugations that were eccentric, central, or diffusely
distributed on top of the PED, whereas 4 of 8 (50%)
Type 3 eyes displayed RPE corrugations most of
which were all diffusely distributed (P = 0.2137).
Multilayering Within Pigment
Epithelial Detachments
Ten of 28 (36%) Type 1 PEDs showed multilayering
at baseline, whereas none of the Type 3 lesions showed
this feature (P = 0.0756).12 By the conclusion of the
study, 9 additional Type 1 eyes developed layering
including the 2 eyes that did not complete the study,
whereas none of the Type 3 eyes ever developed this
feature (P = 0.0017). All eyes that developed RPE tears
failed to demonstrate any layering at baseline or follow-
up. Type 1 eyes that had or developed multilayering
Table 3. Baseline Qualitative Morphologic Components
of All Eyes Separated by NV Type
Type 1
(n = 28),
%
Type 3
(n = 8) P
IRF 8 (29) 8 (100) 0.0004*
DCP exudates 3 (11) 8 (100) ,0.0001*
SRF 26 (93) 5 (63) 0.0615†
Center-involving 14 (54) 1 (20) 0.3326
Eccentric-only 12 (46) 4 (80)
SRHRM 23 (82) 7 (88) 1.000
Lipid bands 2 (7) 2 (25) 0.2075
Reticular pseudodrusen 3 (11) 6 (75) 0.0010*
Serous component in
PED
16 (57) 7 (88) 0.2125
Multilayering in PED 10 (36) 0 (0) 0.0756†
The presence of IRF, DCP exudates, SRF, SRHRM, lipid
bands, and PED contents were determined based on the
SD-OCT. Reticular pseudodrusen was determined through
near-infrared images and SD-OCT. Deep retinal capillary plexus
exudates were deﬁned as hyperreﬂective foci centered at the
level of the inner nuclear layer, and SRHRM was deﬁned as
hyperreﬂective material located external to the retina and internal
to the retinal pigment epithelial layer.
*Statistical signiﬁcance.
†Statistical trends.
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had a 5.3 ± 19 letter gain, which was not found to be
different from eyes without layering that had a 3.3 ± 29
letter gain overall (P = 0.4455) and a 14 ± 13 letter gain
(P = 0.3425) when excluding eyes with RPE tears.
Figure 6 illustrates the development of the multilayering
feature in a typical Type 1 eye with PED, and Table 5
summarizes the prevalence of the feature.
Geographic Atrophy Analysis
The presence of geographic atrophy was identiﬁed
on color photography, near-infrared, and SD-OCT. The
atrophy area was calculated using SD-OCT. None of
the eyes with Type 1 lesions demonstrated geographic
atrophy at baseline, but 15 of 26 (58%) eyes with Type
1 lesions developed geographic atrophy by the end of
the study, including all 5 eyes that sustained RPE tears.
For Type 3 eyes, 1 of 8 (12.5%) had geographic
atrophy at baseline and 6 out 8 (75%) eyes displayed
atrophy by the end of the study. Patients who did not
ﬁnish the study and did not develop atrophy before
their last visit were not included in this subanalysis.
Interestingly, Type 3 eyes that had or developed
geographic atrophy still had a gain of 16 ± 11 letters
Table 4. Differences in Visual Acuity and Morphologic Characteristics of Type 1 and Type 3 Lesions From Baseline to
Final 12-Month Follow-Up
Baseline 12 Months P
BCVA (ETDRS)
Type 1 without RPE tears (ETDRS) 60 ± 9.1 67 ± 19 0.0454*
Type 1 with RPE tears (ETDRS) 60 ± 7.7 53 ± 30 0.3292
Type 3 (ETDRS) 56 ± 9.7 70 ± 14 0.0072*
P
Type 1 without RPE tears vs. Type 3 0.1924 0.3197
Type 1 without RPE tears vs. Type 1 with RPE tears 0.4274 0.1791
Maximal PED height
Type 1 without RPE tears mm 333 ± 199 166 ± 144 0.0010*
Type 1 with RPE tears mm 849 ± 256 469 ± 258 0.0320*
Type 3 mm 357 ± 240 43 ± 59 0.0060*
P
Type 1 without RPE tears vs. Type 3 0.3996 0.0032*
Type 1 without RPE tears vs. Type 1 with RPE tears 0.0043* 0.0286*
PED volume
Type 1 without RPE tears (mm3) 0.97 ± 0.99 0.41 ± 0.46 0.0054*
Type 1 with RPE tears (mm3) 4.2 ± 2.5 1.2 ± 1.1 0.0133*
Type 3 (mm3) 1.4 ± 1.7 0.017 ± 0.024 0.0112*
P
Type 1 without RPE tears vs. Type 3 0.2850 0.0008*
Type 1 without RPE tears vs. Type 1 with RPE tears 0.0221* 0.1065
Mean CRT
Type 1 without RPE tears mm 226 ± 99 213 ± 99 0.1208
Type 1 with RPE tears mm 294 ± 168 308 ± 170 0.4528
Type 3 mm 352 ± 70 239 ± 112 0.0073*
P
Type 1 without RPE tears vs. Type 3 0.0005* 0.0215*
Type 1 without RPE tears vs. Type 1 with RPE tears 0.2115 0.1412
SRF volume
Type 1 without RPE tears, mm3 0.53 ± 0.47 0.012 ± 0.024 ,0.0001*
Type 1 with RPE tears, mm3 1.8 ± 2.0 0.16 ± 0.26 0.0778†
Type 3, mm3 0.18 ± 0.27 0 0.0605†
P
Type 1 without RPE tears vs. Type 3 0.0102* 0.0299*
Type 1 without RPE tears vs. Type 1 with RPE tears 0.1182 0.1313
SRHRM Volume
Type 1 without RPE tears, mm3 0.42 ± 0.47 0.091 ± 0.16 0.0088*
Type 1 with RPE tears, mm3 0.90 ± 0.62 0.30 ± 0.49 0.1223
Type 3, mm3 0.41 ± 0.50 0.0033 ± 0.0071 0.0419*
P
Type 1 without RPE tears vs. Type 3 0.4802 0.0168*
Type 1 without RPE tears vs. Type 1 with RPE tears 0.0834† 0.2011
*Statistical signiﬁcance.
†Statistical trend.
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compared with Type 1 eyes that showed a decrease of
2.4 ± 28 letters (P = 0.0398). Type 1 and Type 3 eyes
that never developed geographic atrophy showed sim-
ilar letter gains (14 ± 9.8 letters for Type 1 and 7.5 ± 13
letters for Type 3, P = 0.3637). Table 5 summarizes the
prevalence of geographic atrophy. At ﬁnal 12-month
follow-up, the area of geographic atrophy was 0.328 ±
0.236 mm2 in Type 1 lesions, excluding eyes with
RPE tears, and 0.324 ± 0.287 mm2 in Type 3 lesion
(P = 0.973). Linear discriminant analysis was per-
formed to evaluate the inﬂuence of baseline PED size,
SRF volume, and SRHRM volume on the development
of geographic atrophy in Type 1 and Type 3 lesions.
Only SRHRM volume was positively correlated with
atrophy development in Type 3 lesions (P = 0.0260).
Anatomic Predictors of Visual Acuity
At baseline, only 8 of 28 (29%) Type 1 eyes had
IRF, whereas all Type 3 eyes had IRF. The baseline
BCVA in these Type 1 eyes with IRF was 55 ± 11
letters (Snellen 20/80), whereas the remaining 20 eyes
without IRF had a baseline BCVA of 62 ± 7.2 letters
(Snellen 20/63) (P = 0.0745). At ﬁnal 12-month
Fig. 5. Hyperreﬂective foci in Type 1 and Type 3 lesions as seen on SD-OCT. In 5 of the Type 1 lesions, a focus of hyperreﬂectivity above the RPE that
mimicked a Type 3 neovascular complex could be identiﬁed. However, as opposed to Type 3 lesions, these “pseudo” hyperreﬂective foci resolved rapidly
with anti-VEGF therapy and without the subsequent scarring or disruption of the outer retina and/or RPE. These 5 lesions are illustrated in comparison with
the 8 Type 3 lesions. Careful examination of SD-OCT is needed to distinguish atypical appearing Type 1 lesions from Type 3 lesions.
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follow-up, 7 of 26 (27%) Type 1 eyes, including all 5
eyes with RPE tears, and 3 of 7 (43%) Type 3 eyes had
residual IRF. Those Type 1 eyes with IRF had a ﬁnal
BCVA of 57 ± 26 letters and those without IRF had
a ﬁnal BCVA of 67 ± 28 letters (P = 0.4024). For
Type 1 eyes that began with IRF, their ﬁnal BCVA
at 12 months was 57 ± 20 letters, whereas those that
began without IRF had a ﬁnal BCVA of 67 ± 29 letters
(P = 0.3703).
At baseline, 26 of 28 (93%) Type 1 and 5 of 8 (63%)
Type 3 eyes had SRF. At ﬁnal 12-month follow-up, 8
of 26 (31%) Type 1 eyes, including 3 with RPE tears,
and none of the Type 3 eyes had residual SRF. At
baseline, Type 1 eyes showed a trend toward worse
vision with SRF (59 ± 8.9 letters with SRF, 66 ± 3.5
letters without SRF, P = 0.0849), and Type 3 eyes
showed a statistically signiﬁcantly lower BCVA for
eyes with SRF (51 ± 6.7 letters with SRF, 64 ± 8.6
letters without SRF, P = 0.04827). At ﬁnal 12-month
follow-up, Type 1 eyes with SRF did not show a worse
vision than those with SRF (66 ± 23 letters with SRF,
63 ± 28 letters without SRF, P = 0.1838). Additionally,
Type 1 and Type 3 eyes that began with baseline SRF
did not show worse ﬁnal vision than those that began
without SRF (Type 1: 63 ± 25 with SRF, 85 ± 60 letters
without SRF, P = 0.3708; Type 3: 64 ± 24 letters with
SRF, 84 ± 49 letters without SRF, P = 0.3973).
At baseline, 14 of 26 (54%) of Type 1 eyes with SRF
had subfoveal involvement, whereas only 1 of 5 (20%)
of Type 3 eyes with SRF did. Type 1 eyes with
subfoveal ﬂuid did not have a statistically signiﬁcant
different baseline BCVA as compared with eyes with
eccentric-only ﬂuid (59 ± 10 letters for subfoveal
involvement, 60 ± 8.2 for eccentric only, P = 0.3338).
Simple linear regression models were run between
BCVA at baseline and ﬁnal 12-month follow-up with
PED volume, PED maximal height, CRT, mean central
SRF thickness, SRF volume, and SRHRM volume for
all Type 1 lesions, Type 1 lesions excluding RPE tears
and Type 3 lesions. The only anatomical feature that
was able to predict BCVA with statistical signiﬁcance
was ﬁnal CRT for Type 1 lesions excluding RPE tears
(P = 0.0185). Simple linear regression was also per-
formed between baseline and ﬁnal BCVA and was not
found to be predictive.
Number of Injections to Achieve Dry State
Of the 33 of 36 patients (26 with Type 1 lesion and
7 with Type 3 lesion) who ﬁnished the study, 4 eyes
with Type 1 lesions never achieved complete regres-
sion of macular edema and/or SRF with our injection
regimen. Of those eyes that did achieve complete
regression, the average number of injections required
to induce a dry state was 1.636 (range, 1–4 injections)
for Type 1 lesions and 1.143 (range, 1–2 injections)
for Type 3 lesions (P = 0.0251). Five of these 22
(23%) Type 1 eyes subsequently had recurrence of
ﬂuid, whereas 2 of 7 (29%) Type 3 eyes had recur-
rence (P = 1.000). Three of the 4 (75%) Type 1 eyes
that never achieved a dry state and 2 of 5 (40%) Type
1 eyes that had recurrence of ﬂuid sustained RPE tears
and had persistent IRF at the edge of the tear. Addi-
tionally, 79% of Type 1 eyes required one or more pro
re nata injections in the latter half of the study,
whereas only 20% of Type 3 eyes did (P = 0.0223).
Discussion
In this prospective investigation, the baseline ana-
tomical characteristics of treatment-naive eyes with
neovascular AMD and PED due to Type 1 or Type 3
NV and the 1-year visual and anatomical response
to intravitreal aﬂibercept injections were studied. In
Fig. 6. Spectral domain optical
coherence tomography evolu-
tion of a multilayered PED in an
eye with Type 1 NV. At base-
line, the treatment-naive PED
harbored serous and ﬁbrovascu-
lar material within the sub-RPE
compartment with overlying
SRHRM SRF. With 1 injection,
there was a remarkable reduction
in the PED and associated
SRHRM (Week 4). At sub-
sequent time intervals (Week 8
and Month 3), the PED matured
and a laminar structure devel-
oped within the PED above
a prechoroidal cleft separating
the PED contents from the
underlying choroid and Bruch
membrane. At Months 6 and 12, some recurrence of serous ﬂuid was seen within the laminar structure with slight enlargement of the PED. This multi-
layering feature was progressive in nature and can be seen in chronic Type 1 PEDs.
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a consecutive group of 266 eyes with newly diagnosed
neovascular AMD, Jung et al3 found a signiﬁcantly
older patient population with Type 3 NV compared
with other neovascular subtypes, which is similar to
our data that showed that Type 3 patients were on
average 5.6 years older than Type 1 patients. Our
study also noted a predominant female population with
both lesion subtypes but especially in Type 3 NV,
which is consistent with previous articles.14
In their cohort, Jung et al noted that 40% of all
lesions in were Type 1, whereas 34% were Type 3 and
17% were mixed lesions. The remaining lesions were
Type 2 (9%).3 In a separate study, Marsiglia et al found
that 47% of unilateral treatment-naive eyes with neo-
vascular AMD harbored Type 1 lesions and 24% har-
bored Type 3 lesions.15 Our study found a distribution
of 74% (28/38) with Type 1 lesions, and 21% (8/38)
with Type 3 lesions, 2.6% (1/38) with mixed lesions,
and 2.6% (1/38) with Type 2 lesion. The greater pro-
portion of Type 1 lesions in our series may be related to
our moderate sample size. Moreover, baseline lesion
components may vary to a certain extent for amongst
different study populations, and we included only one
eye from each patient, whereas Jung et al had 35 pa-
tients with bilateral disease.
Functionally, our patients demonstrated an overall
gain of 6.5 ± 22 letters, with a 4.5 ± 23 letter gain in
Type 1 eyes and a 14 ± 11 letter gain in Type 3 eyes.
Both groups exhibited statistically signiﬁcant improve-
ments in vision, but eyes with Type 3 lesions demon-
strated a 9.2 greater letter gain than eyes with Type 1
lesions. Previous studies have shown similar visual acu-
ity improvements. In a retrospective study of PEDs asso-
ciated with treatment-naive AMD, 3 loading doses of
intravitreal aﬂibercept injections resulted in a mean
vision gain of 9.3 letters.16 Another retrospective study
showed a 7-letter gain after the same aﬂibercept-loading
regimen.17
In our study, slightly more Type 3 eyes developed
GA than Type 1 eyes (58% for Type 1 and 75% for
Type 3), and both groups had similar atrophic areas
(0.328 ± 0.236 mm2 for Type 1 and 0.324 ±
0.287 mm2 for Type 3). However, Type 3 eyes NV
with GA still experienced a gain of 16 ± 11 letters,
whereas Type 1 with GA eyes showed a decrease of
2.4 ± 28 letters. In summary, visual gain was signiﬁ-
cantly greater in eyes with Type 3-associated PED
even with the development of geographic atrophy.
An explanation of this ﬁnding is unclear, but Type 3
lesions may be more responsive to anti-VEGF therapy
as the lesions are located intraretinally and originate
from a different vascular network than Type 1 lesions,
which have a more occult location under the RPE and
originate from the larger choroidal vascular plexus.
Additionally, because Type 3 lesions appears to orig-
inate from the DCP of the parafoveal region,8,11 sub-
sequent was, therefore, rarely central at onset, whereas
Type 1 lesions were often subfoveal. Additionally,
although we evaluated a number of potential factors,
only the presence of baseline SRHRM in Type 3 eyes
as served as a predictive factor for atrophy. Interest-
ingly, PED size does not seem to be a predictive factor
for atrophy development.
At baseline, the mean PED size was similar for Type 1
and Type 3 NV, except for the Type 1 eyes that
developed RPE tears; this latter group had a much
greater baseline PED maximal height and volume (849 ±
256 mm for PED maximal height, 4.2 ± 2.5 mm3 for
PED volume). Type 3 lesions had a signiﬁcantly higher
rate of IRF, DCP exudates and reticular pseudodrusen,
Table 5. Presence of RPE Tears, Multilayering, and Geographic Atrophy at Baseline and Final 12 Month Follow-Up
Separated by NV Type
Baseline 12 Months
Type 1 Type 3 P Type 1 Type 3 P
RPE tears 0/28 (0%) 0/8 (0%) 1.0000 5/26 (19%) 0/7 (0%) 0.5612
Multilayered PED 10/28 (36%) 0/8 (0%) 0.0756* 19/28† (68%) 0/7‡ (0%) 0.0017§
Geographic atrophy 0/28 (0%) 1/8 (12.5%) 0.2432 15/26¶ (58%) 6/8** (75%) 0.4438
All eyes with RPE tears occurred in Type 1 eyes. There was a statistically signiﬁcant greater prevalence of multilayering in Type 1
compared with Type 3 eyes at ﬁnal follow-up and a trend at baseline. More GA was seen in Type 3 eyes than in Type 1 eyes, but that
result did not reach statistical signiﬁcance at baseline or follow-up.
*Statistical trends.
†The eyes of the 2 patients with Type 1 lesions who did not ﬁnish the study began developing multilayering before being lost to follow-up.
‡The eye of the single Type 3 patient who did not ﬁnish the study did not develop multilayering before being lost to follow-up. As
a result, we cannot be certain that the eye would not have developed layering at 12 months, so that eye is not included in this subanalysis.
§Statistical signiﬁcance.
¶The 2 eyes with Type 1 lesions that did not ﬁnish the study did not develop GA before being lost to follow-up. As a result, we cannot
be certain that the eye would not have developed atrophy at 12 months, so those eyes were not included in this subanalysis.
**The eye of the single patient 1 eye with Type 3 lesions that did not ﬁnish the study developed GA before conclusion of the study and
was included.
GA, geographic atrophy.
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and greater CRT, whereas Type 1 lesions had an higher
rate of SRF with greater SRF volume and a greater rate
of PED multilayering at baseline. Although these char-
acteristics of Type 1 and Type 3 lesions have been
previously described,2,3,8,18 to the best of our knowl-
edge, our study is the ﬁrst to directly compare the
prevalence and quality of these features between Type
1 and Type 3 eyes and to prospectively study their
comparative response to treatment. Both Type 1 and
Type 3 lesions showed a decrease in maximal PED
height, PED volume, and SRHRM. Additionally, Type
3 lesions showed a statistically signiﬁcant decrease in
CRT, whereas Type 1 lesions did not. Note that Type 1
lesions had minimal IRF at baseline in contrast to Type
3 lesions. Type 1 lesions showed a statistically signif-
icant decrease in SRF volume, whereas Type 3 lesions
showed only a reduction trend. The origin and patho-
genesis of Type 1 and Type 3 NV may explain these
disparate clinical ﬁndings.
The signiﬁcant association of IRF and middle layer
exudates at the level of the DCP with Type 3 NV is not
at all surprising. Type 3 NV is known to originate at
the DCP, likely driven by various ischemic mecha-
nisms in the parafoveal middle retina, which is
a water-shed-like zone particularly prone to hypoxic
injury.19,20 The presence of IRF and DCP exudates,
which invariably develops in association with the
intraretinal portion of the Type 3 lesions, is therefore
a consequence of leaky intraretinal NV. Additionally,
outer retinal and choroidal ischemia has been
described to drive the Type 3 neovascularization pro-
cess.21 Accordingly, we found an increased rate of
reticular pseudodrusen, which has been associated
with choroidal ischemia in eyes with Type 3 NV con-
sistent with a study by Marsiglia et al.15
Type 1 lesions, however, originate from the
choroid without an intraretinal component. Therefore,
in the absence of intraretinal NV, IRF is unusual
especially with early Type 1 lesions. However, outer
retinal and RPE disruption associated with more
mature or chronic Type 1 lesions can lead to
accumulation of IRF and has been correlated with
a worse visual prognosis.8 Of note, our study found
that Type 1 eyes with IRF at baseline had a trend
toward lower BCVA than that of eyes without IRF
likely because of more chronic or advanced Type 1
lesions. This difference was maintained at the ﬁnal
12-month follow-up visit; however, with the increase
in the range of visual acuity, this difference was not
found to be statistically signiﬁcant. Additionally,
CRT was greater in Type 3 PED eyes both at baseline
and at the ﬁnal 12-month follow-up; and although
both subtypes showed improvement in retinal thick-
ness, Type 3 eyes displayed a much greater decrease
than Type 1. The greater baseline retinal thickness is
the result of more signiﬁcant baseline IRF associated
with Type 3 lesions. Type 3 lesions resolved more
rapidly with anti-VEGF therapy during the early
course, resulting in a smaller difference in thickness
between the 2 lesion types at ﬁnal follow-up.
The predominant exudative sign in Type 1 lesions is
SRF likely as a result of disruption of the RPE pump
mechanism. Type 3 lesions may also develop SRF,
typically eccentric to the PED and its associated
neovascular focus. The association rate, however, is
low because the subretinal compartment is sealed off
by the intraretinal neovascular complex as it grows
into the RPE.2 As a result, Type 1 lesions have a sig-
niﬁcantly greater initial SRF volume and consequently
greater decrease over 12 months (vs. Type 3 lesions)
as shown in our study.
Although our study showed a good functional and
anatomical response to treatment, care must be taken
when associating these two categories of outcomes. The
PED size, SRF volume, mean central SRF thickness, and
SRHRM volume all failed to predict BCVA at baseline
and follow-up for Type 1 and Type 3 eyes with simple
linear regression. Central retinal thickness was found to
be predictive of ﬁnal BCVA in Type 1 eyes without RPE
tears, but was not predictive in Type 3 eyes or the overall
Type 1 cohort. The presence of IRF in eyes with Type 1
NV may indicate a more chronic lesion with a worse
prognosis because of associated disruption of the outer
retina (including the external limiting membrane) and
RPE. Additionally, the presence of SRF in eyes with
Type 3 NV may indicate more adverse or chronic
disease. In fact, at baseline, Type 1 eyes with IRF and
Type 3 eyes with SRF were found to have worse vision
than their counterparts without that type of ﬂuid. At ﬁnal
12-month follow-up, however, no Type 3 eyes had
residual SRF and Type 1 eyes with IRF also had a lower
average BCVA but with a large SD, this difference was
not statistically signiﬁcant. Interestingly, Type 1 eyes
that began with IRF and Type 1 and Type 3 eyes that
began with SRF seemed to maintain a worse BCVA at
ﬁnal 12-month follow-up; however, with the wide range
of visual acuities and small sample size, these ﬁndings
were not statistically signiﬁcant in our study.
In summary, care must always be taken to extrapolate
anatomical success with functional success. This ﬁnding
is consistent with multiple previous reports on AMD,
diabetic retinopathy, and retinal vein occlusions that
show correlations between anatomical outcome and
visual results are variable.22,23 Thus, this underscores
the important point that although OCT-measured ana-
tomical values may serve as useful tools to gauge clin-
ical progress, they cannot substitute as surrogates for
visual acuity measurements in the course of treatment.
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Although Type 1 (excluding RPE tears) and Type 3
PEDs were noted to demonstrate similar dimensions
(maximal height and volume) at baseline, Type 3 PEDs
were smaller at ﬁnal follow-up. In all PEDs, it seemed
that the serous component was the ﬁrst to decrease with
injections. Additionally, 36% of Type 1 lesions had
multilayering12,24 at baseline that increased to 68% at
ﬁnal follow-up. In contrast, none of the Type 3 lesions
ever developed this feature. Multilayering in ﬁbrovas-
cular PEDs has been described as a lamellar layering of
homogenous hyperreﬂective bands with clefts.12,24 This
sub-RPE material is believed to be ﬁbrocellular tissue
that is sequentially deposited over time forming a scar.
In these Type 1 lesions, as the serous component re-
solves, this scaffolding structure along with any residual
ﬁbrovascular material prevents the continued shrinkage
of the PED. In contrast, Type 3 lesions originate above
the RPE and cause a largely serous PED with minimal,
if any, sub-RPE ﬁbrovascular material. As the serous
ﬂuid resolves, there is minimal sub-RPE ﬁbrovascular
tissue, leading to a more complete ﬂattening or resolu-
tion of the PED than Type 1 lesions.
A smaller number of injections was needed for the
complete regression of SRF and IRF in eyes with Type
3 versus Type 1 NV. Additionally, fewer Type 3 eyes
required pro re nata injections in the latter half of the
study. Given the fewer number of injections needed to
achieve and maintain ﬂuid regression and the concern
that excessive intravitreal anti-VEGF injections can
expedite GA, Type 3 lesions may do better with a less
aggressive treatment plan. Additionally, clinical trials
studying different treatment regimens for neovascular
AMD should account for possible differences in
response between the subtypes of AMD when analyz-
ing their results.
The population of Type 1 eyes that experienced RPE
tears showed a much larger PED size at baseline (849 ±
256 mm for PED maximal height and 4.2 ± 2.5 mm3 for
PED volume) and worse visual outcomes at ﬁnal
follow-up. The ﬁnal BCVA of these eyes varied signif-
icantly and depended on the location of the tear. If the
RPE tears affected the fovea, vision was signiﬁcantly
jeopardized while a more eccentric tear supported good
vision. In our study, all tears were either grade 3 or 4,
explaining the poor visual outcome in this group. For
eyes that appear high risk for RPE tears due to a large
PED size (quoted as a height of 600 mm or greater)25
and presence of SD-OCT signs of contraction with
associated SRF, certain studies have proposed the use
a lower dosage of anti-VEGF therapy to reduce con-
tractile forces believed to be the causative factor of RPE
tears26–28 although this awaits further validation.
Our study has limitations. Although it was a pro-
spective study, a priori power calculations were not
performed to set a target sample size for enrollment
and our ﬁnal enrollment sample size was small
especially for Type 3 lesions. As such, comparisons
and correlation analysis that did not reach statistical
signiﬁcance may represent real effects without statis-
tical signiﬁcance because of a small sample size.
However, given the dramatic differences in baseline
morphology and treatment response between Type 1
and Type 3 lesions, many meaningful comparisons
that were statistically signiﬁcant were still found
despite the small sample size. Additionally, our study
was limited to a 1-year duration with a strict treatment
regimen that may or may not be applicable to a real-
world clinical practice. Although long-term clinical
studies for AMD are important given the chronicity of
the disease, we believed that this duration was
adequate to emphasize the remarkable difference in
functional and anatomical outcomes between Type 1
and Type 3 lesions, which was the primary goal.
Longer-term studies would be needed to truly assess
the visual comparisons as GA either secondary to the
natural progression of AMD or expedited by intra-
vitreal injections may play a greater role with time.
Studies investigating the efﬁcacy of intravitreal aﬂi-
bercept therapy of PEDs in AMD have mostly shown
good anatomical response with improvement or no
signiﬁcant change in visual acuity. However, these
investigations are limited in number, are retrospective
in design, small in terms of sample sizes, or use time-
domain OCT.29–34 They also fail to differentiate between
Type 1 and Type 3 NV. Our prospective study shows
excellent functional and anatomical improvement of
PEDs with aﬂibercept monotherapy. However, funda-
mental visual and anatomical differences exist between
PEDs caused of Type 1 versus Type 3 NV at baseline
and at follow-up that may affect diagnosis and therapy.
As illustrated in our study, it is useful for the clinician to
differentiate between the NV subtype at the time of diag-
nosis of the PED because the differences in response to
treatment and the required number of injections may
affect optimal management.
Key words: aﬂibercept, age-related macular degen-
eration, imaging, intravitreal injection, optical coher-
ence tomography, pigment epithelial detachment,
retinal angiomatous proliferation, type 1 neovasculari-
zation, type 3 neovascularization, vascular endothelial
growth factor.
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